Overview

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and tolerability of ASP0367. This study will also evaluate the pharmacokinetics, pharmacodynamics and efficacy on muscle function of ASP0367.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc